a Department of Cardiological, Thoracic and Vascular Sciences , University of Padova , Padova , Italy.
b Veneto Institute of OncologyIOV - IRCCS , Padova , Italy.
Curr Med Res Opin. 2019 Jul;35(7):1187-1190. doi: 10.1080/03007995.2019.1565530. Epub 2019 Jan 24.
To examine the effect of pirfenidone on the survival of patients hospitalized due to acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). The outcomes of 11 consecutive AE-IPF patients who were receiving pirfenidone treatment when they were admitted to a respiratory intensive care unit (RICU) for acute respiratory failure (ARF) (treatment group) were retrospectively compared with those of 9 patients who were not on pirfenidone treatment at admission (control group). The study's primary outcome measure was survival following RICU admission; the patients' mortality rate and the length of time spent in the RICU were also assessed. The treatment group had significantly longer survival than the control group (median survival time: 137.0 [95% CI, 39.0-373.0] versus 16.0 [95% CI, 14.0-22.0] days; = .0009); the hazard ratio for death was 0.2896 (95% CI, 0.09541-0.8791). The treatment group also tended to have a lower RICU mortality rate (3/11 vs. 7/9; = .0698). Pirfenidone significantly improved survival in IPF patients hospitalized for severe acute exacerbation compared to controls.
为了考察吡非尼酮对特发性肺纤维化（IPF）急性加重住院患者生存的影响。回顾性比较了 11 例因急性呼吸衰竭（ARF）入住呼吸重症监护病房（RICU）时接受吡非尼酮治疗的特发性肺纤维化急性加重（AE-IPF）患者（治疗组）与 9 例入院时未接受吡非尼酮治疗的患者（对照组）的结局。本研究的主要观察终点为 RICU 住院后的生存情况；评估了患者的死亡率和 RICU 住院时间。治疗组的生存时间明显长于对照组（中位生存时间：137.0[95%CI，39.0-373.0]与 16.0[95%CI，14.0-22.0]天； = .0009）；死亡风险比为 0.2896（95%CI，0.09541-0.8791）。治疗组的 RICU 死亡率也较低（3/11 与 7/9； = .0698）。与对照组相比，吡非尼酮可显著改善因严重急性加重住院的 IPF 患者的生存。
